Android Apple

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

By Forbes   |   1 month ago
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Monopar Therapeutics' stock (NASDAQ: MNPR) surged due to a licensing deal with Alexion for a promising drug to treat Wilson Disease. MNPR also showed positive results in its pipeline. The stock corrected from $32 to $17.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.